Cargando…

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment

PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal de...

Descripción completa

Detalles Bibliográficos
Autores principales: El Wardani, Mohamad, de Smet, Marc D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883142/
https://www.ncbi.nlm.nih.gov/pubmed/36718434
http://dx.doi.org/10.1016/j.ajoc.2022.101789
_version_ 1784879443217481728
author El Wardani, Mohamad
de Smet, Marc D.
author_facet El Wardani, Mohamad
de Smet, Marc D.
author_sort El Wardani, Mohamad
collection PubMed
description PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery.
format Online
Article
Text
id pubmed-9883142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98831422023-01-29 Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment El Wardani, Mohamad de Smet, Marc D. Am J Ophthalmol Case Rep Case Report PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery. Elsevier 2022-12-31 /pmc/articles/PMC9883142/ /pubmed/36718434 http://dx.doi.org/10.1016/j.ajoc.2022.101789 Text en © 2022 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
El Wardani, Mohamad
de Smet, Marc D.
Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title_full Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title_fullStr Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title_full_unstemmed Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title_short Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
title_sort mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883142/
https://www.ncbi.nlm.nih.gov/pubmed/36718434
http://dx.doi.org/10.1016/j.ajoc.2022.101789
work_keys_str_mv AT elwardanimohamad mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment
AT desmetmarcd mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment